Efficacy and safety assessment of apatinib in patients with advanced gastric cancer: a meta-analysis

Chen, Jianxin; Wang, Junhui

doi:10.2147/ott.s157466

Cited by 8 publications

(11 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Discussionmentioning

confidence: 94%

“…Previous studies have verified the efficacy of a dose of 500-850 mg/day of apatinib in patients with various solid tumors (11)(12)(13)(18)(19)(20)(21)(22)(23)(24)(25)(26). Moreover, meta-analyses showed that the objective response rate and disease control rate were higher with the 850 and 750 mg/day dosages than with a lower dose (18)(19)(20)(21)(22)(23)(24)(25)(26). Most recently, apatinib 750 mg/day showed improved OS in comparison with placebo in a phase III clinical trial when used as second-line therapy in patients with a progressed tumor or those intolerant to previous systemic chemotherapy and/or sorafenib (27).…”

Section: Discussionmentioning

confidence: 94%

“…The eligibility criteria were: (I) 18 The key exclusion criteria were: (I) tumor invasion into intrahepatic or extrahepatic bile ducts, combined hepatocellular cholangiocarcinoma, or fibrolamellar HCC; (II) uncontrolled hypertension; and (III) medical history of myocardial ischemia, myocardial infarction, or arrhythmia.…”

Section: Participantsmentioning

confidence: 99%

See 2 more Smart Citations

Adjuvant apatinib treatment after resection of hepatocellular carcinoma with portal vein tumor thrombosis: a phase II trial

Sun¹,

Zhu²,

Zhou³

et al. 2020

Ann Transl Med

View full text Add to dashboard Cite

Background: Survival after resection of hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) still remains poor. Apatinib, a vascular endothelial cell growth factor receptor 2 inhibitor, has been shown to be safe and effective in patients with advanced HCC, so in the present study its efficacy and safety in the adjuvant setting was explored.Methods: In this single-center, open-label phase II trial, the patients received apatinib (500 mg/day) until they experienced disease recurrence or intolerable toxicity. The primary endpoint was recurrence-free survival (RFS); the secondary endpoints included overall survival (OS) and safety.Results: From a total of 49 patients who were screened between August 2017 and December 2018, 30 study participants received apatinib. According to the Liver Cancer Study Group of Japan classification of PVTT, there were 7, 11, and 12 participants with Vp1, Vp2, and Vp3, respectively. The median duration of treatment was 4.8 months [interquartile range (IQR): 2.0-8.8], and the median dose of apatinib was 339.7 mg/day (IQR: 267.7-500 mg/day). The median follow-up was 14.3 months (IQR: 12.3-19.3). The median RFS was 7.6 months [95% confidence interval (CI): 5.7-9.5 months]. The 1-year RFS rate and the 1-year OS rate were 36.1% and 93.3%, respectively. A total of 29 (96.7%) patients experienced adverse events, and 14 (46.7%) had grade 3 or 4 adverse events. No treatment-related deaths occurred.Conclusions: Apatinib was well tolerated in patients after resection of HCC with PVTT. The median RFS in this group was improved compared with that previously reported.

show abstract

Section: Discussionmentioning

confidence: 94%

Section: Discussionmentioning

confidence: 94%

See 1 more Smart Citation

Adjuvant apatinib treatment after resection of hepatocellular carcinoma with portal vein tumor thrombosis: a phase II trial

Sun¹,

Zhu²,

Zhou³

et al. 2020

Ann Transl Med

View full text Add to dashboard Cite

show abstract

“…VEGFR-2 can be targeted by tyrosine kinase inhibitors (TKIs) such as apatinib (11). Clinical trials have demonstrated the efficacy and safety of apatinib in the treatment of various solid tumors (15)(16)(17)(18). A phase 2 clinical trial (NCT03121846) reported that apatinib was well-tolerated and demonstrated promising antitumor activity, with a median progression-free survival (PFS) of 7.9 months in patients with metastatic STS who had failed chemotherapy (19,20).…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of apatinib in patients with untreated or chemotherapy-refractory soft tissue sarcoma: a multicenter, phase 2 trial

Yu¹,

Zhang²,

Chen³

et al. 2022

Ann Transl Med

View full text Add to dashboard Cite

Background: Anti-angiogenic agents have been reported to exert promising clinical activity for advanced soft tissue sarcoma (STS). Apatinib, a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, is effective and safe for various solid tumors, but its role in STS remains unclear. The aim of this study was to explore the efficacy and safety of apatinib in patients with untreated or chemotherapy-refractory STS.Methods: In this multicenter, single-arm, phase 2 trial, patients aged 18-70 years with untreated or chemotherapy-refractory STS were enrolled and received 500 mg apatinib per day. During treatment, patients were followed up with imaging every 8 weeks. The primary endpoint was the 6-month progressionfree survival (PFS) rate. The secondary endpoints were objective response rate (ORR), overall survival (OS), and adverse events (AEs), which were graded following the National Cancer Institute common terminology criteria for AEs version 4.03.Results: From June 2017 to October 2018, 53 patients were enrolled, 51 of whom received at least one dose of apatinib. Of the 53 patients, 41 (77.4%) had chemotherapy-refractory disease. The median followup was 13.3 months. The 6-and 12-month PFS rates were 46.8% and 25.2%, respectively, with a median PFS of 5.6 months [95% confidence interval (CI): 3.8-9.2 months]. The median PFS was 5.5 months for chemotherapy-refractory patients, 9.1 months for untreated patients, 13.9 months for patients with alveolar soft part sarcoma (ASPS), and 3.7 months for patients with clear cell sarcoma (CCS). The 12-and 24-month OS rates were 58.6% and 44.9%, respectively, with a median OS of 20.0 months (95% CI: 9.2-31.1 months).The median OS was 10.7 months for chemotherapy-refractory patients and not estimated for untreated, ASPS, nor CCS patients. In 50 evaluable patients, the ORR was 18.0% and the disease control rate was 86.0%. These results were similar to those of the per-protocol set. The most common grade 3 or 4 AEs included hypertension [30 (58.8%) of 51 patients], leukopenia [12 (23.5%)], proteinuria [8 (15.69%)], and hematuria [8 (15.69%)]. One patient died of unknown cause.Conclusions: This study suggested that apatinib might be effective and tolerable in patients with untreated or chemotherapy-refractory STS (NCT03064243).

show abstract

“…High NLR, CA125 and low ALB were significantly associated with worse response to therapy and shorter PFS. Interesting, patients in the lower NLR group appeared to demonstrate superior DCR compared to previous studies [24].…”

Section: Discussionmentioning

confidence: 48%

The prognostic value of baseline hematological parameters of peripheral blood in metastatic gastric cancer treated with apatinib

Yang¹,

Zhou²,

Wu³

et al. 2022

J. Cancer

View full text Add to dashboard Cite

Background: There is strong evidence that apatinib is effective in the treatment of third-or later-line advanced metastatic gastric cancer (mGC). Hematology prediction index is a convenient and cheap method to predict the prognosis of disease. However, the prognosis of baseline hematological parameters of peripheral blood, such as neutrophil-to-lymphocyte ratio (NLR), carbohydrate antigen 125 (CA125) and albumin (ALB) on mGC treated with apatinib have not been identified. Methods: We retrospectively analyzed mGC received apatinib between 1 January 2014 and 30 June 2021. Survival analyses were performed using the Kaplan-Meier method and Cox-proportional hazards model. Results: A total of 117 patients were included in this study. The cutoff value of NLR, CA125 and ALB was 2.25, 19.24 U/ml and 37.60 g/L, respectively. The disease control rates (DCR) in the high and low NLR groups were 52.94% and 73.47% (P=0.024); 48.28% and 74.58% (P=0.003) in high and low CA125 groups; 72.97% and 41.86% (P=0.001) in high and low ALB groups. By survival analysis, increasing NLR (P=0.003), CA125 (P<0.001) and decreasing ALB (P<0.001) predicted a shorter PFS after apatinib. NLR (P=0.015), CA125 (P=0.004) and ALB (P=0.005) were significantly predictors for PFS in mGC treated with aptinib. Conclusion: Increasing NLR, CA125 and decreasing ALB were associated with poorer clinical efficiency and prognosis after apatinib treatment.

show abstract

Efficacy and safety assessment of apatinib in patients with advanced gastric cancer: a meta-analysis

Cited by 8 publications

References 21 publications

Adjuvant apatinib treatment after resection of hepatocellular carcinoma with portal vein tumor thrombosis: a phase II trial

Adjuvant apatinib treatment after resection of hepatocellular carcinoma with portal vein tumor thrombosis: a phase II trial

Efficacy and safety of apatinib in patients with untreated or chemotherapy-refractory soft tissue sarcoma: a multicenter, phase 2 trial

The prognostic value of baseline hematological parameters of peripheral blood in metastatic gastric cancer treated with apatinib

Contact Info

Product

Resources

About